No Data
No Data
ResMed Is Maintained at Buy by B of A Securities
Express News | Resmed Inc : BofA Global Research Raises Price Objective to $270 From $240
ResMed Initiated at Outperform by Baird
Australian Healthcare Players See Wage Indexation Benefits, Margin Expansion in Fiscal 2025, Jarden Research Says
ResMed Inc. (NYSE:RMD) Is a Favorite Amongst Institutional Investors Who Own 74%
AU Evening Wrap | ASX Surpasses 8200 as Fed Cuts Rates; BHP Rallies on Morgan Stanley Buy Rating
No Data
No Data
151453268 witso : Wow jess you are pulling the trigger and heading for the safe havens, probably good traffic control considering the state of uncertainty our leaders keep promoting, and i use the term leader very loosely. I can only sit tight have a Pepsi and hope my hair doesn’t catch fire. PS more of a coke drinker